

**Predictors of Treatment Failure with
Sofosbuvir/Daclatasvir Regimen for 12
Weeks in Chronic HCV Egyptian Patients**

Thesis

*Submitted for Partial Fulfillment of the Degree of
Master in Tropical Medicine*

By

Ahmed Tawheed Mohammed Mowafy
M.B.B.Ch.

Under supervision of

Professor/ Nadia Abdelaaty Abdelkader

*Professor of Tropical Medicine
Faculty of Medicine – Ain Shams University*

Professor / Mohamed El Kassas

*Assistant Professor of Endemic Medicine
Faculty of Medicine - Helwan University*

Dr/ Mohamed Salah Eldin

*Lecturer of Tropical Medicine
Faculty of Medicine - Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبب أنك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Professor/ Nadia Abdelaaty Abdelkader**, Professor of Tropical Medicine Faculty of Medicine – Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Professor / Mohamed El Kassas**, Assistant Professor of Endemic Medicine Faculty of Medicine - Helwan University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr/ Mohamed Salah Eldin**, Lecturer of Tropical Medicine Faculty of Medicine - Ain Shams University, for his great help, active participation and guidance.*

Ahmed Tawheed Mohammed Mowafy

List of Contents

Title	Page No.
List of Tables	5
List of Figures	8
List of Abbreviations	10
Introduction	1
Aim of the Work	17
Review of Literature	
▪ Hepatitis C Virus	18
▪ HCV Treatment & DAAs	45
Patients and Methods	69
Results	73
Discussion	95
Summary	106
Conclusion	108
Recommendations	109
References	110
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
<u>Table in Review</u>		
Table (1):	Extrahepatic manifestations categories according to affected system.....	33
Table (2):	Extrahepatic manifestations categories according to the strength of association.....	34
Table (3):	Types of cryoglobulinaemia.	35
Table (4):	Diagnostic criteria of cryoglobulinemic syndrome.	35
Table (5):	Risk Factors of cirrhosis.....	38
Table (6):	Child-Pugh classification of severity of liver disease (1964).	41
Table (7):	Available DAAs.	52
Table (8):	Relevant definitions for IFN free HCV therapies.	63
Table (9):	SVR rates of DAA treatment in HCV GT4-6 infection.....	64
Table (10):	Laboratory and imaging investigations.	71

List of Tables Cont...

Table No.	Title	Page No.
Table in Result		
Table (1):	Demographic data of the studied patients.....	74
Table (2):	Distribution of special habits and risk factors of the studied patients.....	75
Table (3):	Distribution of comorbidities of the studied patients.....	76
Table (4):	Distribution of liver function tests and HCV RNA PCR among the studied patients.....	77
Table (5):	Distribution of CBC parameters and Kidney Function tests (KFTs).....	79
Table (6):	Distribution of liver echo-pattern detected by abdominal ultrasound.....	80
Table (7):	Number of responders and non-responders at week 16 and week 24.....	81
Table (8):	Comparison between responders and non-responders regarding demographic data.....	83
Table (9):	Comparison between responders and non-responders regarding special habits and risk factors.....	84
Table (10):	Comparison between responders and non-responders regarding comorbidities.....	85
Table (11):	Comparison between responders and non-responders regarding ALT, AST, HCV RNA Quantitative PCR and AFP.....	86
Table (12):	Comparison between responders and non-responders regarding LFTs.....	89
Table (13):	Comparison between responders and non-responders regarding CBC and KFTs.....	90
Table (14):	Comparison between responders and non-responders regarding liver echo-pattern.....	91

List of Tables Cont...

Table No.	Title	Page No.
Table (15):	Logistic regression analysis for predictors of treatment failure 12 weeks after treatment.	92
Table (16):	Multi-variate logistic regression analysis for predictors of treatment failure 12 weeks after treatment.....	94

List of Figures

Fig. No.	Title	Page No.
<u>Figure in Review</u>		
Figure (1):	Hepatitis C virus particle structure.....	23
Figure (2):	HCV life cycle and site of action of DAAs.....	24
Figure (3):	HCV genome organization and translation	25

List of Figures Cont...

Fig. No.	Title	Page No.
Figure in Results		
Figure (1):	Number of patient who completed the treatment and those who missed their follow up or stopped treatment.....	73
Figure (2):	Patients with abnormal echo-pattern among all patients.....	80
Figure (3):	Patients with treatment failure on week 16.	81
Figure (4):	Patients with SVR 12 and patients with treatment failure on week 24.	82
Figure (5):	Comparison between responders and non-responders in diabetic patients.....	85
Figure (6):	Comparison between HCV RNA PCR in responders and non-responders.....	86
Figure (7):	Comparison between ALT levels in responders and non-responders.	87
Figure (8):	Comparison between AST levels in responders and non-responders.	87
Figure (9):	Comparison between AFP levels in responders and non-responders.	88
Figure (10):	Showing comparison between responders and non-responders regarding echo-pattern of the liver.	91
Figure (11):	Receiver operating characteristic curve (ROC) for predictors of treatment failure	93

List of Abbreviations

Abb.	Full term
<i>AFP</i>	<i>Alpha-fetoprotein</i>
<i>ALT</i>	<i>Alanine transaminase</i>
<i>ARF</i>	<i>Alternate reading frame</i>
<i>ART</i>	<i>Abbott Real Time HCV RNA assay</i>
<i>AST</i>	<i>Aspartate aminotransferase</i>
<i>AUC</i>	<i>Area under curve</i>
<i>BMI</i>	<i>Body Mass Index</i>
<i>BOC</i>	<i>Boceprevir</i>
<i>BT</i>	<i>Before treatment</i>
<i>CAP/CTM</i>	<i>Cobas AmpliPrep / Cobas TaqMan analyzer</i>
<i>CBC</i>	<i>Complete blood picture</i>
<i>CD4</i>	<i>Cluster of differentiation 4</i>
<i>CGs</i>	<i>Cryoglobulins</i>
<i>DAA</i>	<i>Direct-acting antivirals</i>
<i>DAC</i>	<i>Daclatasvir</i>
<i>DHS</i>	<i>Demographic health survey</i>
<i>DM</i>	<i>Diabetes mellitus</i>
<i>E1, E2</i>	<i>Envelope</i>
<i>EBR</i>	<i>Elbasvir</i>
<i>EC</i>	<i>Effective concentrations</i>
<i>EIAs</i>	<i>Enzyme-linked immuno-assays</i>
<i>ELISA</i>	<i>Enzyme-linked immunosorbent assay</i>
<i>EMA</i>	<i>European Medicines Agency</i>
<i>GN</i>	<i>Glomerulonephritis</i>
<i>GT</i>	<i>Genotype</i>
<i>GZR</i>	<i>Grazoprevir</i>
<i>Hb</i>	<i>Hemoglobin</i>
<i>HBV</i>	<i>Hepatitis B Virus</i>
<i>HCC</i>	<i>Hepatocellular carcinoma</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HIV</i>	<i>Human immunodeficiency virus</i>

List of Abbreviations Cont...

Abb.	Full term
<i>HLA</i>	<i>Human Leukocyte Antigen</i>
<i>HPS/CTM</i>	<i>High-Pure System/ COBAS TaqMan</i>
<i>HVRI</i>	<i>Hypervariable region 1</i>
<i>IgG</i>	<i>Immunoglobulin G</i>
<i>IgM</i>	<i>Immunoglobulin M</i>
<i>IL28B</i>	<i>Interleukin 28B</i>
<i>INR</i>	<i>International normalized ratio</i>
<i>ITP</i>	<i>Immune thrombocytopenic purpura</i>
<i>IU/L</i>	<i>International units per litre</i>
<i>IV</i>	<i>Intravenous</i>
<i>KFT</i>	<i>Kidney Function Tests</i>
<i>LDV</i>	<i>Ledipasvir</i>
<i>LFT</i>	<i>Liver Function Tests</i>
<i>MC</i>	<i>Mixed cryoglobulinaemia</i>
<i>MELD</i>	<i>Model for end-stage liver disease</i>
<i>MPGN</i>	<i>Membranoproliferative glomerulonephritis</i>
<i>mRNA</i>	<i>Messenger RNA</i>
<i>NCCVH</i>	<i>National Committee for Control of Viral Hepatitis</i>
<i>NCR</i>	<i>Noncoding region</i>
<i>NK</i>	<i>Natural killer</i>
<i>NS</i>	<i>Nonstructural protein</i>
<i>NS5A</i>	<i>Nonstructural protein 5A</i>
<i>NS5B</i>	<i>Nonstructural protein 5B</i>
<i>NTR</i>	<i>Nontranslated region</i>
<i>NULR</i>	<i>Null response to PEGIFN</i>
<i>OBV</i>	<i>Ombitasvir</i>
<i>ORF</i>	<i>Open-reading frame</i>
<i>PAD</i>	<i>Peripheral arterial disease</i>
<i>PCR</i>	<i>Polymerase chain reaction</i>
<i>PCT</i>	<i>Porphyria cutanea tarda</i>

List of Abbreviations Cont...

Abb.	Full term
<i>PEG-IFN</i>	<i>Pegylated interferon alfa-2a</i>
<i>PI</i>	<i>Protease inhibitors</i>
<i>PR</i>	<i>Partial response</i>
<i>PTV/r</i>	<i>Paritaprevir /r</i>
<i>RBV</i>	<i>Ribavirin</i>
<i>REL</i>	<i>Relapse</i>
<i>RF</i>	<i>Rheumatoid fact0r</i>
<i>RIBA</i>	<i>Recombinant immunoblot assay</i>
<i>RNA</i>	<i>Ribonucleic acid</i>
<i>ROC</i>	<i>Receiver operating characteristic curve</i>
<i>SMV</i>	<i>Simeprevir</i>
<i>SOF</i>	<i>Sofosbuvir</i>
<i>SOF/DAC</i>	<i>Sofosbuvir / <u>Daclatasvir</u></i>
<i>SVR</i>	<i>Sustained Virological Response</i>
<i>TLC</i>	<i>Total leucocytic count</i>
<i>TLV</i>	<i>Telaprevir</i>
<i>U/S</i>	<i>Ultrasonography</i>
<i>UNOS</i>	<i>United Network for Organ Sharing</i>
<i>UTR</i>	<i>Untranslated regions</i>
<i>VEL</i>	<i>Velpatasvir</i>
<i>WBC</i>	<i>White blood cells</i>
<i>WHO</i>	<i>World Health Organization</i>

INTRODUCTION

HCV infection is one of the main causes of chronic liver disease worldwide (*Lavanchy et al., 2011*).

The long-term impact of HCV infection, ranging from minimal histological changes to cirrhosis with or without hepatocellular carcinoma (HCC). The estimated number of chronically infected HCV patients worldwide is about 180 million (*Messina et al., 2015*).

Egypt has the highest national-level HCV prevalence in the world, the percentage of adults aging from 15-59 testing positive on the HCV RNA test is 7% of the Egyptian population (*Kandeel et al., 2017*).

HCV genotype (GT) 4, is the most common variant in the HCV epidemic in Egypt with more than 90% of infections due to genotype 4 (*Messina et al., 2015*).

The morbidity of HCV in untreated patients as regard liver cirrhosis, liver cell failure and hepatocellular carcinoma represent a major health problem and economic burden (*Bruno et al., 2007*).

In 2006, in recognition of the enormity of the HCV problem and burden of disease in Egypt, the Minister of Health established the National Committee for Control of Viral Hepatitis (NCCVH), the available regimen was Peginterferon

alfa (PEG-a), 350000 patients had received therapy with SVR rates for patients treated with the PEG-IFN- α 2a and alfa-2b were 54%-59% respectively (*El-Akel et al., 2017*).

The predictive factors of therapy response are also related to the virus and hosts, and they can be classified as clinical, biochemical, immunologic and genetic factors.

Male gender, advanced liver fibrosis, human immunodeficiency virus (HIV) and HBV coinfection, insulin resistance, poor treatment adherence, high viral load (≥ 600.000 UI/mL) and African ancestry have been related with the failure of interferon (IFN) based therapies, particularly with dual therapy (pegylated interferon and ribavirin) (*Cavalcante and Lyra, 2015*).

In early clinical trials of interferon and ribavirin, a baseline HCV RNA level over 800,000 IU/ml was found to be associated with a 9% lower chance of cure. Subsequent studies found that patients with high viral load had a 15 to 39% lower chance of achieving an SVR.

Recent advances in drug development have led to a number of direct anti-viral agents (DAAs) which deliver high rates of SVR with substantial improvements in the side effect profiles.

One of these drugs, sofosbuvir (SOF), a potent inhibitor of the HCV NS5B polymerase, has been approved for the treatment of HCV in Egypt since 2014 (*Youssef et.al. 2017*).

These regimens include either single DAA therapy SOF with RBV for 24 wks, or dual DAA combination therapy in the form of simeprevir plus Sofosbuvir, Sofosbuvir/Daclatasvir, Sofosbuvir plus ledipasvir, Grazoprevir/elbasvir and Paritaprevir/ ombitasvir/ ritonavir plus ribavirin for 12 wks (*EASL, 2016*).

Daclatasvir, another DAA which is one of the NS5A inhibitors which is associated with great results in HCV clearance, also it is pan-genotypic (*Asselah et al., 2014*).

Patients infected with HCV genotype 4 can be treated with daily dose of Sofosbuvir and Daclatasvir for 12 weeks. Also Sofosbuvir/ Daclatasvir and Ribavirin for 24 weeks can be used for treatment of non-responders to Sofosbuvir based therapy according to *EASL (2016)*.

In November 2015 the NCCVH issued a new protocol in which the Sofosbuvir/Daclatasvir for 12 weeks has been included to treat the Easy to treat Egyptian HCV patients according to the following criteria:

- INR<1.2.
- Serum Albumin > 3.5 gm/dl.
- Platelets Count > 150,000.
- Total bilirubin < 1.2 mg/dl.